LadRx Corporation
CYTR
Other OTC0.09
USD
+0.00
- -
CIK
0000799698
ISIN
US2328286081
CUSIP
232828608
Return %
Stock
S&P500
1Y
-81.63
26.53
3Y
-86.57
76.60
5Y
-94.67
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Steven Kriegsman
- Full Time Employees
- 3
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 11726 San Vicente Blvd Ste 650 Los Angeles CA United States of America 90049
- IPO Date
- Nov 10, 1986
- CIK
- 0000799698
- Website
- cytrx.com
- Similar Companies
- Business
- LadRx Corporation, formerly CytRx Corporation, is a biopharmaceutical company that discovers and develops therapeutics primarily to treat cancer patients through its proprietary Linker Activated Drug Release (LADR) technology platform. This technology features an organic backbone attached to chemotoxic agents, such as novel derivatives of auristatin and maytansinoid, that target tumors by binding to circulating albumin for delivery and release within the tumor microenvironment; lead candidates include LADR7, LADR8, LADR9 and LADR10. Additional programs encompass aldoxorubicin, a modified version of doxorubicin in phase II clinical development for pancreatic cancer; and albumin companion diagnostic (ACDx) to identify responsive patients. The company was founded in 1985 and is headquartered in Los Angeles, California. LadRx relaunched under its current name in September 2022 to emphasize the LADR platform, while aldoxorubicin was licensed to ImmunityBio Inc. for up to $330 million in milestones and royalties; arimoclomol was sold to Orphazyme A/S (now Zevra Therapeutics Inc.) for milestone payments and royalties targeting Niemann-Pick disease Type C and Gaucher disease. Recent activities include advancing LADR7 through IND-enabling studies, planning a pre-NDA meeting with the FDA for aldoxorubicin pending $1.5 million in funding, and pursuing capital for NDA submission.
Sorrento Therapeutics (OTCMKTS:SRNEQ) versus LadRx (OTCMKTS:CYTR) Financial Contrast
Analyzing LadRx (OTCMKTS:CYTR) & SQZ Biotechnologies (NYSE:SQZ)
Contrasting Sorrento Therapeutics (OTCMKTS:SRNEQ) and LadRx (OTCMKTS:CYTR)
LadRx Corporation, Inc. to Present at the Virtual Life Science Investor Forum March 13th
LadRx Planning NDA Submission under 505(b)(2) for Aldoxorubicin and Other Updates
LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License
Best Penny Stocks To Buy? 4 To Watch This Week With Potential Catalysts
CytRx Highlights Orphazyme's Submission of European Marketing Authorisation for Arimoclomol to Treat Niemann-Pick Disease Type C